Myeloma

The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients

**The Rise of China’s CAR-T Therapy: New Hope for Multiple Myeloma Patients** #CARTTherapy #CART #MultipleMyeloma #BloodCancer #patientstory China’s CAR-T cell therapy has emerged as a highly effective and proactive option for treating relapsed and refractory multiple myeloma, bringing new hope to patients facing limited treatment options. This innovative therapy has shown significant effectiveness in clinical Read More

November 5th,2024 Myeloma , CAR-T , patient story

New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma

**New Advances in Chinese CAR-T Cell Therapy: CD27 Armored BCMA CAR-T Shows Potential in Treating Relapsed Multiple Myeloma** #BCMA #CD27#CARTCellTherapy #RRMM #MM #MultipleMyeloma #CART Relapsed and refractory multiple myeloma (RRMM) is a challenging blood cancer that poses significant obstacles for patients. Although several BCMA (B-cell maturation antigen) targeting CAR-T cell therapies have been developed, achieving Read More

November 5th,2024 Myeloma

CAR-T Cell Therapy as a New Option for Treating Multiple Myeloma

**CAR-T  Cell Therapy as a New Option for Treating Multiple Myeloma** “CAR-T cell therapy has now become a new option for treating patients with relapsed and refractory multiple myeloma, with hopes of changing the difficult situation in myeloma treatment where treatments are either ineffective or unavailable,” said Jin Jie, Director of the Hematology Department at the Read More

November 4th,2024 Myeloma , CAR-T

China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients

**China’s CAR-T Therapy as a Beacon of Hope: A New Light for Multiple Myeloma Patients** #CAR-TTherapy #MultipleMyeloma #PatientStory #CancerSurvivor In recent years, CAR-T cell therapy in China has spearheaded a revolution in hematologic cancer treatment. This innovative immunotherapy has brought a glimmer of hope to many patients, especially those with relapsed and refractory cases who Read More

October 31st,2024 Myeloma , CAR-T

What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China?

# What Kind of Multiple Myeloma Patients Are Suitable for CAR-T Therapy in China? #MultipleMyeloma #CAR_Therapy #MM #CART #RRMM #Hematology **Multiple Myeloma** (MM) is a malignant hematological disease that affects plasma cells. In recent years, various drugs and treatment methods, such as proteasome inhibitors, immunomodulatory drugs, and autologous stem cell transplantation, have significantly improved the Read More

October 24th,2024 Myeloma , CAR-T

Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma

### Recommended Myeloma Expert – Professor Qiu Luguo – A Leading Specialist in Hematology and Multiple Myeloma We at Advanced Medicine In China are proud to have Professor Qiu Luguo as our contracted expert. He provides telemedicine consultations for our international patients and can arrange for them to travel to China through a special fast-track Read More

October 23rd,2024 Myeloma

**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients**

**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients** #CARTTherapy #MultipleMyeloma #BCMA #CD19 #JAMAOncology #MM #HRMM #DualTarget Once again, a Chinese medical team is at the forefront of innovation, making significant strides in the field of CAR-T cell therapy. A recent study published in *JAMA Oncology* (B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Read More

October 15th,2024 Myeloma

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient**

**China’s CAR-T Therapy Brings Complete Remission for Primary Refractory Multiple Myeloma Patient** #MultipleMyeloma #CARTtherapy #BloodCancer #CompleteRemission #CART       Multiple Myeloma (MM) is a malignant blood disorder characterized by abnormal proliferation of plasma cells, which causes damage to vital organs. Patients with high-risk cytogenetic abnormalities like 17p deletion, t(4;14) translocation, and t(14;16) translocation face an even worse prognosis. Read More

October 3rd,2024 Myeloma

BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma

**BCMA CAR-T Therapy Paves New Path for Treating High-Risk Multiple Myeloma** Multiple Myeloma (MM) is a malignant tumor originating from plasma cells, known for its complex biology and treatment resistance, presenting significant challenges to patients’ survival. For high-risk MM, especially in cases of relapse and refractory disease after multiple lines of therapy, treatment options become Read More

September 30th,2024 Myeloma

Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma

**Uncovering the Hidden Threat: How Serum Protein Electrophoresis Helps Diagnose Multiple Myeloma** #MultipleMyeloma #BloodCancer #SerumProteinElectrophoresis #MM #Mprotein #monoclonalprotein #SPE As we age, it’s common to experience certain health issues—unexplained anemia, bone pain, fractures, nausea, or abnormal urine changes. Many may dismiss these symptoms as a result of aging, poor diet, or even mild illness. However, Read More

September 24th,2024 Myeloma

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation**

**Treatment for Multiple Myeloma: China’s BCMA×CD3 Bispecific Antibody Proposed for Breakthrough Therapy Designation** #MultipleMyeloma #BCMAxCD3 #BispecificAntibody #Immunotherapy #GR1803 #NMPA #RRMM Recently, GR1803, an injectable solution developed by Genrix Bio, has been proposed for the “Breakthrough Therapy Designation” by the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). This innovative drug targets Read More

September 6th,2024 Myeloma

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma

China’s Fully Human BCMA CAR-T Therapy: Bringing New Hope for High-Risk Relapsed/Refractory Multiple Myeloma Multiple Myeloma (MM) is a complex and aggressive cancer originating from plasma cells, posing significant treatment challenges due to its resistance to therapy. For patients with high-risk MM, especially those who experience relapse after multiple lines of treatment, finding an effective Read More

August 29th,2024 Myeloma , CAR-T